Jaguar Health Files Definitive Proxy Statement

TL;DR

Jaguar Health filed its proxy statement for the shareholder meeting. Vote your shares!

AI Summary

Jaguar Health, Inc. filed its definitive proxy statement (DEF 14A) on May 21, 2024, for its annual meeting of stockholders. The filing details information required for the proxy statement, including matters to be voted on by shareholders. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the annual meeting, including any proposals or director elections, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.

Key Numbers

• 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• 0001104659-24-063603.txt (document) — Filing identifier
• 20240521 (date) — Filing date
• 200 PINE STREET SUITE 400 (address) — Company business address
• SAN FRANCISCO (location) — Company city
• DE (location) — State of incorporation

FAQ

Key Financial Figures

• $0.0001 — s of our voting common stock, par value $0.0001 per share (the "Common Stock"), and 99.
• $6,500 — LC to solicit proxies for a base fee of $6,500 plus reimbursement of reasonable out-of

Filing Documents

• tm2411645-2_def14a.htm (DEF 14A) — 846KB
• lg_jaguarhealth-4c.jpg (GRAPHIC) — 33KB
• sg_lisaaconte-bw.jpg (GRAPHIC) — 12KB
• bc_tsr-bw.jpg (GRAPHIC) — 47KB
• bc_netloss-bw.jpg (GRAPHIC) — 45KB
• px_24jaguarproxy1pg01-bw.jpg (GRAPHIC) — 216KB
• px_24jaguarproxy1pg02-bw.jpg (GRAPHIC) — 316KB
• px_24jaguarproxy1pg03-bw.jpg (GRAPHIC) — 398KB
• 0001104659-24-063603.txt ( ) — 2252KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT The following table sets forth information regarding the beneficial ownership of shares of our Common Stock as of May 13, 2024 for: each person known to us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock; each of our named executive officers; each of our directors; and all directors and named executive officers as a group. Information with respect to beneficial ownership has been furnished by each director, executive officer or beneficial owner of more than 5% of our Common Stock. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting and investment power with respect to the securities. Except as otherwise provided by footnote, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of Common Stock shown as beneficially owned by them. The number of shares of Common Stock used to calculate the percentage ownership of each listed person includes the shares of Common Stock underlying options or warrants or convertible securities held by such persons that are currently exercisable or convertible or exercisable or convertible within 60 days of May 13, 2024, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Percentage of beneficial ownership is based on (i) 293,353,560 shares of Common Stock and (ii) 2,014,131 shares of non-voting common stock, par value $0.0001 per share (convertible into 9 shares voting common stock after the effects of the reverse stock split effected through January 23, 2023) outstanding as of May 13, 2024. Except as otherwise set forth below, the address of each beneficial owner listed in the table below is c/o Jaguar Health, Inc., 200 Pine Street, Suite 400, San Francisco, California 94104. Voting Common Stock Name and address of bene

View Full Filing

View this DEF 14A filing on SEC EDGAR